A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs AMG-301 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Amgen
- 09 Aug 2018 Planned End Date changed from 18 Dec 2018 to 4 Feb 2019.
- 09 Aug 2018 Planned primary completion date changed from 31 Aug 2018 to 16 Oct 2018.
- 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.